Marker Therapeutics, Inc.

Monthly Archives: August 2016

TapImmune Appoints Michael J. Loiacono as Chief Financial Officer

August 25, 2016, Jacksonville, FL,, TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More

TapImmune Enters into Definitive Agreements to raise $8.5 Million from the Exercise of Outstanding Warrants and in a Private Placement from New Investors

...Company has Applied for Listing on Nasdaq Capital Market JACKSONVILLE, Florida, August 11, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today the entry into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million.
Read More